SPARC (Sun Pharma)/K0706 (NCT03655236):
This study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. K0706 works to suppress an enzyme called Abl tyrosine kinase, whose activity has been linked to several processes associated with Parkinson’s development, such as oxidative stress and alpha-synuclein-induced neurodegeneration.
https://www.proseekstudy.com/
https://clinicaltrials.gov/ct2/show/results/NCT03655236
Contera Pharma and Bukwang/SHINE study
This study is to evaluate the efficacy of JM-010, a combination of two serotonin agonists, on levodopa-induced dyskinesias (LID). The serotoninergic system is thought to play a role in LIDs due to loss of the normal mechanisms in dopamine regulation
https://clinicaltrials.gov/ct2/show/NCT04377945
Rutgers – High Fiber in Parkinson’s disease
The purpose of the research is to determine the effects of a high-fiber nutritional supplement (HFS) on the bacteria, viruses, and fungi that live in different regions of the body in those with Parkinson's disease (PD). We will compare the bacteria, viruses, and fungi of those with PD to those without PD (healthy controls). We will also examine the effects of transplanting stool from humans into laboratory mice with or without Parkinson-like pathology to understand how the microbiome influences the brains of animals. We can use this information to get a better understanding of how changing the microbiome might help humans.
https://clinicaltrials.gov/ct2/show/NCT04976959
Additional studies for Parkinson’s and other disorders at RWJ will be listed as they are approved.
